Mechanisms linking angiotensin II and atherogenesis

Current Opinion in Lipidology

Volumn 13, Issue 5, 2002, Pages 505-512

  Strawn, William B ^a   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Angiotensin II type 1 receptor; Atherosclerosis; Blood pressure; Lipids

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; NITRIC OXIDE; ANGIOTENSIN II;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DYSLIPIDEMIA; ENDOTHELIUM CELL; ESTROGEN DEFICIENCY; FIBROGENESIS; HUMAN; HYPERTENSION; LEUKOCYTE MIGRATION; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR SMOOTH MUSCLE; ANIMAL; ARTERIOSCLEROSIS; METABOLISM; PATHOLOGY; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; MACROPHAGES; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS;

EID: 0036774946     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200210000-00006     Document Type: Review

References (84)

1. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 2000; 205:1177-1178.
2. Stary HC. The development of calcium deposits in atherosclerotic lesions and their persistence after lipid regression. Am J Cardiol 2001; 882A:16E-19E.
3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 1059:1135-1143.
4. Rosenfeld ME. Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex. Arterioscler Thromb Vasc Biol 2002; 223:361-363.
5. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 892A:3A-9A.
6. Ferrario CM. Angiotensin I, angiotensin II and their biologically active peptides. J Hypertens 2002; 205:805-807.
7. Nickenig G, Michaelsen F, Muller C, et al. Post-transcriptional regulation of the AT1 receptor mRNA. Identification of the mRNA binding motif and functional characterization. FASEB J 2001; 158:1490-1492.
8. Olivares-Reyes JA, Smith RD, Hunyady L, et al. Agonist-induced signaling, desensitization, and internalization of a phosphorylation-deficient AT1A angiotensin receptor. J Biol Chem 2001; 27641:37761-37768.
9. Saito Y, Berk BC. Angiotensin II-mediated signal transduction pathways. Curr Hypertens Rep 2002; 42:167-171.
10. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT1 receptor regulation. Circulation 2002; 1054:530-536.
11. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 1053:393-396.
12. Bader M, Peters J, Baltatu O, et al. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 2001; 792-793:76-102.
13. Singh BK, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia: relevance in atherogenesis and therapy of coronary heart disease. Indian Heart J 2001; 534:511-518.
14. Rakugi H, Kamide K, Ogihara T. Vascular signaling pathways in the metabolic syndrome. Curr Hypertens Rep 2002; 42:105-111.
15. Wassmann S, Laufs U, Stamenkovic D, et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002; 10517:2083-2091.
16. Chobanian AV. Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease. Curr Hypertens Rep 2002; 42:93-95.
17. White M, Racine N, Ducharme A, de Charnplain J. Therapeutic potential of angiotensin II receptor antagonists. Expert Opin Investig Drugs 2001; 109:1687-1701.
18. Pitt B. Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn? Am J Hypertens 2002; 151 (Pt 2):22S-27S.
19. Halkin A, Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med 2002; 1122:126-134.
20. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002; 151 (Pt 2):9S-13S.
21. Escobar E. Hypertension and coronary heart disease. J Hum Hypertens 2002; 16 (Suppl 1):S61-S63.
22. Stanley AG, Patel H, Knight AL, Williams B. Mechanical strain-induced human vascular matrix synthesis: the role of angiotensin II. J Renin Angiotensin Aldosterone Syst 2000; 11:32-35.
23. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Pressure promotes angiotensin II-mediated migration of human coronary smooth muscle cells through increase in oxidative stress. Hypertension 2002; 392 (Pt 2):433-437.
24. Aikawa R, Nagai T, Kudoh S, et al. Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension 2002; 392:233-238.
25. Sakamoto H, Aikawa M, Hill CC, et al. Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. Circulation 2001; 1041:109-114.
26. Chen HJ, Li DY, Saldeen T, et al. Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT1 receptor blockade in hyperlipidemic rabbits. Biochem Biophys Res Commun 2001; 2822:474-479.
27. Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000; 102:1970-1976.
28. Watanabe T, Pakala R, Katagiri T, Benedic: CR. Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. J Hypertens 2001; 196:1065-1073.
29. Strehlow K, Wassmann S, Bohm M, Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med 2000; 326:386-389.
30. Song K, Shiota N, Takai S, et al. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys. Atherosclerosis 1998; 1381:171-182.
31. Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100:2131-2134.
32. Mehta JL, Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J Am Coll Cardiol 2002; 399:1429-1435.
33. Kume N, Kita T. Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis. Curr Opin Lipidol 2001; 124:419-423.
34. Li DY, Zhang YC, Philips MI, et al. Up-regulation of endothelial receptor for oxidized low-density lipoprotein LOX-1 in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999; 849:1043-1049.
35. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 28719:2570-2581.
36. Doggrell SA. Class benefits of AT1 antagonists in Type 2 diabetes with nephropathy. Expert Opin Pharmacother 2002; 35:625-628.
37. Uchida T, Okumura K, Ito T, et al. Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats. Clin Exp Pharmacol Physiol 2002; 295-296:381-385.
38. Kassab E, McFarlane S, I, Sower JR. Vascular complications in diabetes and their prevention. Vasc Med 2001; 64:249-255.
39. Dell'Italia LJ, Rocic P, Lucchesi PA. Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease. Curr Probl Cardiol 2002; 271:6-36.
40. Ceriello A, Motz E. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. N Engl J Med 2002; 3469:705-707.
41. Golovchenko I, Goalstone ML, Watson P, et al. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000; 879:746-752.
42. Hattori Y, Suzuki M, Hattori S, Kasai K. Vascular smooth muscle cell activation by glycated albumin Amadori adducts. Hypertension 2002; 391:22-28.
43. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 10519:2296-2302.
44. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci 2002; 3231:17-24.
45. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 376:1450-1457.
46. Baumer AT, Wassmann S, Ahlbory K, et al. Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene. Br J Pharmacol 2001; 1343:579-584.
47. Rossig L, Hermann C, Haendeler J, et al. Angiotensin II-induced up-regulation of MAP kinase phosphatase-3 mRNA levels mediates endothelial cell apotosis. Basic Res Cardiol 2002; 971:1-8.
48. Bascands JL, Girolami JP, Troly M, et al. Angiotensin II induces phenotype-dependent apoptosis in vascular smooth muscle cells. Hypertension 2001; 386:1294-1299.
49. Leclercq B, Jaimes EA, Raij L. Nitric oxide synthase and hypertension. Curr Opin Nephrol Hypertens 2002; 112:185-189.
50. Munzel T, Keaney JF, Jr. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001; 10413:1571-1574.
51. Stralin P, Marklund SL. Vasoactive factors and growth factors alter vascular smooth muscle cell EC-SOD expression. Am J Physiol Heart Circ Physiol 2001; 2814:H1621-H1629.
52. Mueller C, Baudler S, Welzel H, et al. Identification of a novel redox-sensitive gene, Id3, which mediates angiotensin II-induced cell growth. Circulation 2002; 10520:2423-2428.
53. Wang HD, Johns DG, Xu S, Cohen RA. Role of superoxide anion in regulating pressor and vascular hypertrophic response to angiotensin II. Am J Physiol Heart Circ Physiol 2002; 2825:H1697-H1702.
54. Wingler K, Wunsch S, Kreutz R, et al. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001; 3111:1456-1464.
55. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 904:E58-E65.
56. Brosnan MJ, Hamilton CA, Graham D, et al. Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002; 202:281-286.
57. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001; 381:100-104.
58. Kobayashi N, Nakano S, Mita S, et al. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Ther 2002; 3012:459-466.
59. Kataoka C, Egashira K, Inoue S, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 392:245-250.
60. Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle ceils. Arterioscler Thromb Vasc Biol 2001; 2112:1896-1901.
61. Niebauer J, Tsao PS, Lin PS, et al. Cholesterol-induced up-regulation of angiotensin II and its effects on monocyte-endothelial interaction and superoxide production. Vasc Med 2001; 63:133-138.
62. Prasad A, Koh KK, Schenke WH, et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 2001; 1422:248-253.
63. Rahman ST, Lauten WB, Khan QA, et al. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure renin-angiotensin system antagonists, oxidation, and inflammation. Am J Cardiol 2002; 896:686-690.
64. Strawn WB, Dean RH, Ferrario CM. Novel mechanisms linking angiotensin II and early atherogenesis. J Renin Angiotensin Aldosterone Syst 2000; 11:11-17.
65. Strawn WB. Pathophysiological and clinical implications of of AT1 and AT2 angiotensin II receptors in metabolic disorders: hypercholesterolemia and diabetes. Drugs 2002; 62 (Suppl 1):31-41.
66. Khan BV, Navalkar S, Khan QA, et al. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 2001; 386:1662-1667.
67. Rodgers KE, Xiong S, DiZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol 2002; 495:403-411.
68. Barton M, Haudenschild CC. Endothelium and atherogenesis: endothelial therapy revisited. J Cardiovasc Pharmacol 2001; 38 (Suppl 2):S23-S25.
69. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2002; 31:1-15.
70. Luft FC. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 2002; 111:59-66.
71. Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 2001; 339:1673-1690.
72. Ko L, Maitland A, Fedak PW, et al. Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins. Ann Thorac Surg 2002; 734:1185-1188.
73. Keidar S, Heinrich R, Kaplan M, Aviram M. Oxidative stress increases the expression of the angiotensin-II receptor type 1 in mouse peritoneal macrophages. J Renin Angiotensin Aldosterone Syst 2002; 31:24-30.
74. Hayek T, Kaplan M, Raz A, et al. Ramipril admnistration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis 2002; 1611:65-74.
75. Kaplan M, Aviram M, Knopf C, Keidar S. Angiotensin II reduces macrophage cholesterol efflux: a role for the AT-1 receptor but not for the ABC 1 transporter. Biochem Biophys Res Commun 2002; 2905:1529-1534.
76. Figueroa JE, Vijayagopal P. Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis 2002; 1622:261-268.
77. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001; 197:1245-1254.
78. Scholkens BA, Landgraf W. ACE inhibition and atherogenesis. Can J Physiol Pharmacol 2002; 804:354-359.
79. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 10112:1372-1378.
80. Fukuhara M, Geary RL, Diz DI, et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 351 (Pt 2):353-359.
81. Kubo-Inoue M, Egashira K, Usui M, et al. Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery. Am J Physiol Heart Circ Physiol 2002; 2824:H1478-H1484.
82. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 374:1047-1052.
83. Nishimoto M, Takai S, Kim S, et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 2001; 10411:1274-1279.
84. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 2001; 386:1382-1387.